GUIDE TO DETERMINING THE TYPE OF NYXOID YOU NEED TO CLAIM

This guide aims to assist Service Providers in determining which type of Nyxoid nasal spray they have provided in order to correctly claim the right product under the Take Home Naloxone (THN) Program in the Pharmacy Programs Administrator (PPA) Portal. Both products contain naloxone (1.8mg/actuation nasal spray, 2x1 actuation).

Nyxoid

- The product will have *Nyxoid* (naloxone hydrochloride dihydrate 2.2 mg) written on the front
- The product may cost less than the Nyxoid (UK) when ordering from your wholesaler (noting PPA has no visibility on the prices pharmacies are charged by wholesalers)
- This product is sponsored by Mundipharma

Nyxoid (UK) *temporary S19A approval*

This product is S19A approved by the Therapeutic Goods Administration (TGA) and can temporarily be provided under the THN Program between 1 October 2023 to 31 January 2024. This product has been approved because there is both a shortage of Nyxoid registered in Australia and the medicine is needed in the interest of public health.

- The product will have *Nyxoid 1.8* written on the front of the packaging and have contact details for the sponsor Pro Pharmaceuticals attached
- The product may cost more than the other Nyxoid from your wholesaler (noting PPA has no visibility on the prices pharmacies are charged by wholesalers)
- This product is sponsored by Pro Pharmaceuticals Group and has arrived from the United Kingdom
- This product has temporary S19A approval by the Therapeutic Goods Administration (TGA).

Service Providers are reminded to ensure the information they enter into the claim form is true and correct (this includes selecting the correct Nyxoid product for reimbursement) and that all supplies included in any claims were provided in accordance with the PPA General Terms and the THN Program Rules.